Cantor initiated protection on Aquestive Therapeutics, Inc. AQST, a pharmaceutical firm with 5 commercialized merchandise.
The corporate additionally collaborates with pharmaceutical firms to deliver new molecules to market utilizing its applied sciences, like PharmFilm. Aquestive is advancing a late-stage proprietary product candidate for extreme allergic reactions, together with anaphylaxis, and an earlier-stage epinephrine prodrug topical gel for varied dermatology situations.
Cantor highlights that the corporate’s secret sauce is concentrated on the PharmFilm expertise, which delivers lively pharmaceutical components by way of oral routes (e.g., buccal, sublingual, and lingual). The core focus of the story proper now could be Anaphylm, which is in pre-NDA stage improvement for Sort 1 allergic reactions.
Cantor initiates with an Obese score and a worth forecast of $17.
Additionally Learn: Optimism Round Aquestive Because it Strikes Ahead With Extreme Allergy, Baldness Candidate
Earlier this month, the corporate reaffirmed the New Drug Software first quarter 2025 submission steering for Anaphylm and confirmed that no extra grownup medical trials are vital earlier than NDA submission. The corporate has commenced pediatric trials within the U.S. and Canada.
Cantor writes that Aquestive shares are buying and selling effectively beneath estimated peak gross sales for Anaphylm regardless of the corporate producing vital knowledge supporting its comparable profile to epinephrine auto-injectors (and, in some conditions, enhancements).
“We’d be patrons for the potential of this program alone and assume shares may very well be up >200% in 2025 if accepted,” the Cantor analyst writes.
Cantor writes that Anaphylm’s sublingual epinephrine may shake up the epinephrine auto-injector market as:
- The product is extremely transportable, in regards to the measurement of a postage stamp, and might slot in a pocket or behind a cellphone.
- It could be faster and simpler to make use of than conventional auto-injectors, with fewer steps concerned, which may make it extra interesting for sufferers and caregivers.
Anaphylm U.S. advertising and marketing software submission makes up most of Cantor’s income projections for Aquestive.
Value Motion: AQST inventory is up 7.31% at $3.86 finally verify Tuesday.
Learn Subsequent:
Picture: Shutterstock/ Andrey_Popov.
Market Information and Information delivered to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.